Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT‐ACS Trial

BackgroundThe Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non‐ST‐Segment Elevation Myocardial Infarction (SELECT‐ACS) trial suggested beneficial effects of inclacumab, a monoclonal antibody directed against P‐selectin, on periproc...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Barbara E. Stähli, Catherine Gebhard, Valérie Duchatelle, Daniel Cournoyer, Thibaut Petroni, Jean‐François Tanguay, Stephen Robb, Jessica Mann, Marie‐Claude Guertin, R. Scott Wright, Philippe L. L'Allier, Jean‐Claude Tardif
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2016-10-01
coleção:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Assuntos:	acute coronary syndrome inflammation myocardial infarction percutaneous coronary intervention thrombosis
Acesso em linha:	https://www.ahajournals.org/doi/10.1161/JAHA.116.004255
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!